SCHEMBL217245

SCHEMBL217245

O=c1cnc2cccnc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.43
PARP1 P09874 1/20 0.43
DAO P14920 3/20 0.41
MAPKAPK2 P49137 1/20 0.41
RPS6KA3 P51812 1/20 0.41
CSNK2A1 P68400 1/20 0.41
PLK3 Q9H4B4 1/20 0.41
FEN1 P39748 1/20 0.39
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
PMP22 Q01453 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
CCNB2 O95067 2/20 0.36
CDK1 P06493 2/20 0.36
CCNB1 P14635 2/20 0.36
GSK3B P49841 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8793075 0.98 AURKA (0.42) AURKAPARP1DAOMAPKAPK2RPS6KA3
Hydrochloric Acid SCHEMBL29397868 0.98 AURKA (0.42) AURKAPARP1DAOMAPKAPK2RPS6KA3
Trifluoroacetic Acid SCHEMBL34473163 0.86 L3MBTL1 (0.40) AURKAPARP1DAOFEN1ALDH1A1
SCHEMBL29623547 0.72 MAPK1 (0.46) CCNB2CDK1CCNB1GSK3BCDK5
SCHEMBL167394 0.72 MAPK1 (0.46) CCNB2CDK1CCNB1GSK3BCDK5
SCHEMBL29396007 0.71 ALDH1A1 (0.59) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL37862 0.71 ALDH1A1 (0.59) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL28647710 0.71 ALDH1A1 (0.40) AURKADAOMAPKAPK2RPS6KA3CSNK2A1
SCHEMBL2165024 0.71 AURKA (0.42) AURKAPARP1DAOFEN1ALDH1A1
SCHEMBL1416592 0.71 MAPT (0.50) AURKAPARP1MAPKAPK2RPS6KA3CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175998-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF DUNAD THERAPEUTICS, LTD. (GB) 2024-08-29 WO claimed
WO-2024175999-A2 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF DUNAD THERAPEUTICS LTD. (GB) 2024-08-29 WO claimed
EP-4196480-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2023-06-21 EP claimed
CN-115956080-A Bicyclic compounds, compositions containing them and their use 贝达药业股份有限公司 2023-04-11 CN claimed
EP-1268443-B1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2009-07-29 EP claimed
EP-1549655-B1 SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-01-21 EP claimed
WO-2004031189-A1 PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2004-04-15 WO claimed
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-19 US claimed
EP-1268443-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SmithKline Beecham p.l.c. (GB) 2003-01-02 EP claimed
EP-0736532-B1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA MEDICA AG (DE) 2002-05-15 EP claimed
WO-2001074788-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2001-10-11 WO claimed
EP-0992240-A1 THERAPEUTIC AGENT FOR ERECTION FAILURE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-04-12 EP claimed
EP-0736532-A1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA Medica Aktiengesellschaft (DE) 1996-10-09 EP claimed
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 US disclosed
EP-4496785-B1 PESTICIDAL AND HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF AG PLENUS LTD (IL) 2025-12-24 EP disclosed
WO-2025245046-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2025-11-27 WO disclosed
EP-0736532-A1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA Medica Aktiengesellschaft (DE) 1996-10-09 EP disclosed
EP-0736532-A1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA Medica Aktiengesellschaft (DE) 1996-10-09 EP disclosed
EP-0736532-A1 Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation ASTA Medica Aktiengesellschaft (DE) 1996-10-09 EP disclosed
US-4296114-A 3,4-Dihydro-3-oxopyrido[2,3-b]-pyrazines, compositions and use thereof FISONS LIMITED (GB) 1981-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use MSH6, MSH2, PMS2 AURKA 4108/4885PARP1 3766/4885DAO 1065/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 AURKA 2585/4885PARP1 180/4885DAO 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.